Source comparison
CJC-1295 No DAC vs GHRP-2 Acetate — Which Works Better?
Research conducted at Monash University in 2004 demonstrated that Modified GRF (1-29). The peptide commercially known as CJC-1295 no DAC. Produces a 2–10 fold increase in growth hormone secretion within 30 minutes of administration, with plasma levels returnin
This comparison does not assign a generated winner or score.
- Research conducted at Monash University in 2004 demonstrated that Modified GRF (1-29). The peptide commercially known as CJC-1295 no DAC. Produces a 2–10 fold increase in growth hormone secretion within 30 minutes of administration, with plasma levels returning to baseline within 3 hours. GHRP-2 Acetate triggers even sharper GH spikes. Up to 15-fold increases within 20 minutes. But follows the same rapid clearance pattern. Neither peptide sustains supraphysiological GH levels the way exogenous recombinant growth hormone does. What they do instead is amplify your body's existing pulsatile secretion, which is why stacking them produces results neither achieves alone.
- Our team works directly with researchers using both peptides in controlled protocols. The distinction that matters isn't which peptide is 'better'. It's understanding how each one manipulates the growth hormone axis through entirely different receptor pathways.
- What's the difference between CJC-1295 no DAC and GHRP-2 Acetate?
- CJC-1295 no DAC (Modified GRF 1-29) is a growth hormone releasing hormone (GHRH) analogue with a half-life of approximately 30 minutes, amplifying endogenous GH pulses without receptor desensitization. GHRP-2 Acetate is a growth hormone releasing peptide (GHRP) that binds ghrelin receptors (GHS-R1a), triggering immediate, dose-dependent GH secretion spikes independent of GHRH signaling. The two peptides act on separate receptor systems. GHRH receptors in the pituitary vs ghrelin receptors in both the pituitary and hypothalamus. Which is why synergistic stacking protocols consistently produce 3–5× greater GH output than either peptide administered alone.
- The main confusion around CJC-1295 no DAC vs GHRP-2 Acetate which better comparison stems from conflating these peptides with their modified counterparts. Specifically CJC-1295 with DAC (Drug Affinity Complex), which extends half-life to 6–8 days but chronically elevates GH in a way that disrupts natural pulsatility. This article covers the receptor-level mechanisms that differentiate no-DAC CJC from GHRP-2, the half-life and dosing implications of each peptide's pharmacokinetics, and the exact stacking protocols researchers use to maximize synergistic GH release without inducing receptor downregulation.